TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Enhancement of Cerebral Vasoreactivity and Cognition by Intranasal Insulin in Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Diabetes group:~* 30 men and women aged \>50 years old diagnosed with T2DM and treated \> 5 years with oral agents~* Diabetes severity will be assessed from diabetes duration, hemoglobin A1C, and fasting glucose levels.~Control group:~* 30 healthy men and women aged \>50 years selected to have the same age and sex distributions as the diabetic subjects~* Normotensive, not treated for any systemic disease, and have normal fasting blood glucose.~Exclusion Criteria:~* Type 1 Diabetes Mellitus~* History of severe hypoglycemia or hypoglycemic episode during home baseline monitoring~* Positive stress test for CAD or other ischemic conditions~* Carotid stenosis \> 50% by medical history~* History of a clinically documented stroke~* Treatment with any medications administered intranasally including intranasal steroids~* Any previous adverse or allergic reactions to insulin~* Acute or unstable medical condition including Myocardial infarction or major illness and surgery within six months~* Liver or renal failure or transplant~* Uncontrolled hypertension (systolic BP \>180 and/or diastolic BP \>100 mm Hg or subjects taking more than 3 antihypertensive medications)~* Seizure disorders~* Malignant tumors~* Clinical dementia (by history) or inability to follow details of the protocol(MMSE (Mini Mental Status Exam) score (≥3 points below the Comparative Normal Value for the subject's age group and education level, or ≤ 24)~* Current recreational drug or alcohol abuse~* Morbid obesity (BMI \>40)~* Inability to obtain permission for participation from the primary care physician~* Transcranial Doppler (TCD) exclusion criterion - poor insonation window and TCD signal~* MR exclusion criteria - any metal or bioimplants not compatible with 3 Tesla MRI and claustrophobia~* Clinically significant and movement limiting hip, knee and/or back disorders or injury, and rheumatoid arthritis

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- Insulin vs. placebo (Type: EXPERIMENTAL): Comparisons of acute effects of intranasal insulin or placebo (saline) on cerebral blood flow and cognition in healthy controls and type 2 diabetes.
- Healthy vs. Diabetic (Type: OTHER): Comparisons of acute effects of intranasal insulin or placebo (saline) on cerebral blood flow and cognition in healthy controls and type 2 diabetes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Primary Sjögren's Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of primary Sjögren's syndrome~* ESSDAI score ≥ 6~Exclusion Criteria:~* Secondary Sjögren's syndrome~* Receiving cyclosphosphamide, corticosteroid bolus with dose over 1 mg/kg, rituximab, belimunab, other immunosuppressives.~* At significant risk for thromboembolic event~* Clinically significant systemic infection~* Significant elevated risk for infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- CFZ533 active- Cohort 2 (Type: EXPERIMENTAL): multiple doses of CFZ533 intravenous infusion
- CFZ533 placebo- Cohort 2 (Type: PLACEBO_COMPARATOR): multiple doses of placebo intravenous infusion
- CFZ533 active - Cohort 1 (Type: EXPERIMENTAL): multiple doses of CFZ533 s.c. injection
- CFZ533 placebo - Cohort 1 (Type: PLACEBO_COMPARATOR): multiple doses of placebo s.c. injection
- CFZ533 Treatment Arm 1 - Cohort 3 (Type: EXPERIMENTAL): multiple doses of CFZ533 s.c. injection
- CFZ533 Treatment Arm 2 - Cohort 3 (Type: EXPERIMENTAL): Single dose of CFZ533 i.v. infusion and multiple doses of CFZ533 s.c. injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Very Low Protein Diet or Dialysis in Uremic Elderly?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. males or females \>= 70 years of age~2. RRF 5-7 ml/min/1.73 m2~3. left ventricular ejection fraction \>40%~4. signed informed written consent~Exclusion Criteria:~1. diabetes~2. severe cerebral disease~3. proteinuria \>3 g/24 h~4. severe hepatic failure~5. active malignancy~6. COPD requiring supplementary oxygen~7. AIDS, or HIV-positive

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: 95 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Open Label Extension Study of Romiplostim (AMG 531) in Thrombocytopenic Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Must have previously completed a romiplostim ITP study~* Platelet count ≤ 50 x 10 \^9/L~* Written informed consent~Exclusion Criteria:~* Bone marrow stem cell disorder or new active malignancies diagnosed since enrollment in the previous romiplostim ITP study~* Received any alkylating agents within 4 weeks before screening visit or anticipated use during the time of the proposed study~* Currently enrolled in or has not yet completed at least 4 weeks since ending device or drug trial(s) (other than the previous romiplostim ITP study), or subject is receiving other investigational agent(s) other than romiplostim~* Not using adequate contraceptive precautions~* Not available for follow-up assessments~* Has any kind of disorder that compromises the ability of the participant to give informed consent and does not have a legally-acceptable representative and/or is unable to comply with study procedures.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Romiplostim (Type: EXPERIMENTAL): Romiplostim weekly subcutaneous dosing based on screening weight and platelet count. Starting dose of 1 µg/kg up to a maximum dose of 10 µg/kg.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of S-1 in Combination With Gemcitabine as First-Line Treatment in Patients With Advanced Biliary Tract Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 1.histologically confirmed biliary tract carcinoma (including intrahepatic bile duct, extrahepatic bile duct, gallbladder, and ampulla of vater);~* 2.metastatic or unresectable disease;~* 3.no history of chemotherapy or radiotherapy for biliary tract cancer;~* 4.presence of at least one measurable tumor lesion which is defined as lesions that can be accurately measured in at least 1 dimension with longest diameter (LD) ≥20 mm using conventional techniques or ≥10 mm with spiral CT and MRI; measurable lymph nodes must be ≥15 mm in the short axis;~* 5.adequate hematopoietic function which is defined as below:~  1. hemoglobin level ≥ 9 g/dL;~ 2. absolute neutrophil count (ANC) ≥ 1,500/mm3;~ 3. platelet count ≥ 100,000/mm3;~* 6.adequate hepatic function which is defined as below:~  1. total bilirubin ≤ 1.5 times upper limit of normal (ULN) and \< 2 mg/dL, or total bilirubin \< 3 mg/dL if biliary drainage was performed;~ 2. Alanine aminotransferase (ALT) ≤ 3 x ULN or ALT ≤ 5 x ULN in the presence of liver metastasis;~* 7.adequate renal function: creatinine clearance rate (CCr) ≥ 60 mL/min ((based upon 24-hour urine collection or calculated by Cockroft-Gault formula);~* 8.age of 20 years or above;~* 9.ECOG performance status 0-1;~* 10.life expectancy of at least 12 weeks;~* 11.ability to take oral medication;~* 12.ability to understand and willingness to sign a written informed consent document.~Exclusion Criteria:~* 1.other malignancy within the past 5 years except for adequately treated basal or squamous cell skin cancer or cervical cancer in situ;~* 2.history or known presence of brain metastasis;~* 3.presence of grade 2 or above ascites or pleural effusion;~* 4.presence of grade 2 or above diarrhea;~* 5.presence of mental disease or psychotic manifestation;~* 6.active or uncontrolled infection;~* 7.significant medical conditions that is contraindicated to study medication or render patient at high risk from treatment complications based on investigator's discretion;~* 8.pregnant women or nursing mothers, or positive pregnancy test for women of childbearing potential. Patients with childbearing potential shall have effective contraception for both the patient and his or her partner during the study.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- S-1/Gemcitabine (Type: EXPERIMENTAL): single-arm

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of a Rehabilitation Program on Physical Performance and Disease Self-management in Rheumatoid Arthritis.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* medical diagnosis of RA according to the American College of Rheumatology (ACR) criteria~* between 18 and 66 years of age~Exclusion Criteria:~* severe disease activity (Disease Activity Score:DAS-28 \> 5.1)~* cardiac or pulmonary diseases resulting in restrictions in their ability to follow a physical exercise program~* a Steinbrocker classification of functional capacity in RA ≥ 3~* no stable medication for the RA~* intra-articular injections during the time of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 66 Years
- Healthy Volunteers: f

Study Arms:
- fit-program (Type: EXPERIMENTAL): Participants in the intervention group followed an eight week multi-disciplinary group rehabilitation program, consisting of a physical exercise part and an educational component.
- waiting list control group (Type: OTHER): The waiting-list control group was allowed to enter the FIT program for rehabilitation after the study period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ambispective Clinical Evaluation of Sophono™

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Any subject who currently has or who has had the Sophono implant (including those who have been explanted)~* Has or has had Sophono implant for 3 months or longer~Exclusion Criteria:~* Subject has implant but is unable or unwilling to perform audiologic testing~* Subject is currently participating in another clinical study and has not been approved for concurrent enrollment by the Study Sponsor

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: None
- Healthy Volunteers: None

Study Arms:
- Subjects (Type: None): Diagnosed with Conductive Hearing Loss (CHL), Single-Sided Deafness (SSD)and mixed Hearing Loss (HL) who currently have or have had the Sophono implant

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Fixed Dose Combination Versus Free Combination of Tiotropium and Olodaterol in COPD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Male or female patients.~* Patients 40 years of age or older.~* Patients with a smoking history \> 10 pack years.~* Diagnostic of COPD with Post-bronchodilator FEV1 (Forced Expiratory Volume in one second) \>= 30% and \<80% of predicted normal and Post-bronchodilator FEV1/FVC (Forced Vital Capacity) \<70% at screening.~* Symptomatic patients with CAT (COPD Assessment Test TM) score \>= 10 at screening.~* Further inclusion criteria apply.~Exclusion criteria:~* COPD exacerbation or symptoms of lower respiratory tract infection within 6 weeks prior to screening.~* Patients with a current diagnosis of asthma.~* Further exclusion criteria apply.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FDC of tiotropium + olodaterol (Type: EXPERIMENTAL): Fixed Dose Combination of tiotropium + olodaterol
- Free combination tiotropium + olodaterol (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of 12-wk Treatment With Two Doses of Tiotropium Respimat in Cystic Fibrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~1. Male or female patients~2. Diagnosis of Cystic Fibrosis (positive sweat chloride test or two identifiable mutations)~3. Pre-bronchodilator FEV1 greater/equal 25% of predicted values~Exclusion criteria:~1. Significant history of allergy/hypersensitivity~2. Hypersensitivity to study drug~3. Participation in another trial~4. Female patients who are pregnant or lactating~5. Female patients of childbearing potential~6. Patients who have started a new medication for CF within 4 weeks of screening~7. Patients with known substance abuse~8. Clinically significant disease other than CF

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tiotropium Respimat 2.5 mcg (Type: EXPERIMENTAL): patient to receive low dose tiotropium once daily
- Tiotropium Respimat 5 mcg (Type: EXPERIMENTAL): patient to receive high dose tiotropium once daily
- Placebo Respimat (Type: PLACEBO_COMPARATOR): patient to receive placebo once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Basic Study of Fabricating Biomorphic Crowns

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* single crown restoration needed in posterior quadrants~* the antagonist of the abutment tooth is purely natural or received minimum restorations that does not change its morphology too much~* no orthodontic treatment history~* stable occlusion~* no parafunctional movements existed~Exclusion Criteria:~* sequential crown restorations needed~* the morphology of the antagonist of the abutment tooth has been largely changed by previous treatment~* no contact exists between the abutment tooth and its antagonist~* orthodontic treatment history~* unstable occlusion~* existed parafunctional movements~* participated in other clinical studies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- FGP design (FGP, AVR) (Type: EXPERIMENTAL): use functional generated path to execute different occlusal surface designs of the artificial crown and evaluate its efficacy
- conventional design (CON) (Type: NO_INTERVENTION): use conventional method to execute different occlusal surface designs of the artificial crown and evaluate its efficacy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Mirtazapine Versus Placebo in Functional Dyspepsia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Functional dyspepsia according to Rome II criteria~* Weight loss of \> 5% body weights~Exclusion Criteria:~* Organic GI pathology~* History of upper gi tract surgery~* Major depression or anxiety~* Use of antidepressants in the last 2 months~* Prokinetic drugs or spasmolytic drugs~* Analgesic use (except paracetamol)~* Pregnancy or lactation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Mirtazapine (Type: ACTIVE_COMPARATOR): mirtazapine 15 mg daily
- Placebo (Type: PLACEBO_COMPARATOR): Placebo once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: CC-5013 With or Without Dexamethasone in Treating Patients With Primary Systemic Amyloidosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~DISEASE CHARACTERISTICS:~* Histologically confirmed primary systemic (AL) amyloidosis~  * Tissue amyloid deposits or positive fat aspirate~* Meets 1 of the following criteria for AL type disease:~  * Serum or urine monoclonal protein by immunofixation electrophoresis~ * Plasmacytosis of bone marrow by monoclonal staining for kappa- or lambda-light chain isotype~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* SWOG 0-2~Life expectancy~* Not specified~Hematopoietic~* White blood count\> 3,000/mm\^3~* Hemoglobin \> 8 g/dL~* Platelet count \> 100,000/mm\^3~* Absolute neutrophil count \> 1,000/mm\^3~Hepatic~* Bilirubin ≤ 2 times upper limit of normal (ULN)~* aspartate aminotransferase (AST) and Alanine Aminotransferase (ALT) ≤ 2 times ULN~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Prior thalidomide for AL amyloidosis allowed~Chemotherapy~* More than 4 weeks since prior cytotoxic chemotherapy~Endocrine therapy~* Prior steroids for AL amyloidosis allowed~Radiotherapy~* More than 4 weeks since prior radiotherapy~Surgery~* Prior surgery allowed~Other~* Recovered from all prior therapy~Exclusion Criteria:~* No secondary or familial amyloidosis~* No multiple myeloma, defined as ≥ 30% plasma cells in bone marrow biopsy specimen OR lytic bone lesions~* No prior CC-5013~Renal~* No dialysis~Cardiovascular~* No symptomatic cardiac arrhythmia~* No oxygen-dependent restrictive cardiomyopathy~Other~* No untreated or uncontrolled infection~* No other malignancy except basal cell skin cancer or carcinoma in situ of the cervix or breast~* No other serious medical illness that would preclude study participation~* No history of hypersensitivity reaction to thalidomide~* HIV negative~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- revlimid (Type: EXPERIMENTAL): lenalidomide 15 mg/day, for 21 days with 7 days rest (28 day cycle) with or without dexamethasone 20 mg daily (10 mg BID) on Days 1-4, 9-12, and 17-20 of every other 28-day cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Progressive prostate cancer~* Medical or surgical castration with testosterone less than 50 ng/dl~* One or two prior chemotherapy regimens. At least one chemotherapy regimen must have contained docetaxel~* Eastern Cooperative Oncology Group (ECOG) performance status 0-2~* Adequate bone marrow, hepatic, and renal function~* Able to swallow the study drug and comply with study requirements~* Informed consent~Exclusion Criteria:~* Metastases in the brain or active epidural disease~* Another malignancy within the previous 5 years~* Clinically significant cardiovascular disease~* Gastrointestinal disorder affecting absorption

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Enzalutamide (Type: EXPERIMENTAL): Formerly MDV3100
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Metformin Treatment of Pregnant Women With Polycystic Ovary Syndrome: a Pilot Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosis polycystic ovary syndrome (PCOS ) before pregnancy~* BMI 27-40 kg/m2~* Human chorionic gonadotropin, beta subunit (HCG-beta) verified pregnancy week 5-8~* At least one of the following criteria: (1) serum testosteron \> 2,5 nmol/L; (2) Sex hormone binding globulin (SHBG) \< 30 nmol; (3) Fasting C-peptid \> 1,0 nmol/L; (4) Menstrual disturbances: oligo-/amenorrhea or metrorrhagia; (5) Hirsutism~Exclusion Criteria:~* known liver disease or ALAT \> 60 IU/L~* S-creatinin \> 130 micromol/L~* diabetes mellitus~* alcohol or drug abuse~* peroral steroid treatment (except inhalation steroids)~* use of cimetidine, anticoagulant, erythromycin or other macrolides~* not suitable for other reasons

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Metformin (Type: EXPERIMENTAL): Metformin 850 mg x 2 daily
- placebo (Type: PLACEBO_COMPARATOR): Placebo 1 tablet x 2 daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete